NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
14 trialsNCT07227402 2026-03-16
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT07011719 2026-03-13
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3 Recruiting
NCT07293351 2026-03-04
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05536141 2026-02-27
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT06716853 2026-02-09
TEM-GU
Genenta Science
Phase 1/2 Terminated
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03798626 2026-01-27
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT06026410 2026-01-02
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed